What is suramin?

Suramin is a medication used to treat malaria and other infectious disorders. It is believed to work by inhibiting protein synthesis in disease-causing parasites, leading to their death. 

It has also been used in the treatment of some forms of cancer and inflammatory diseases. It is administered intravenously and is mainly used in the treatment of severe malaria and in cases of human immunodeficiency virus (HIV) infections. It has also been used in the treatment of some forms of cancer, such as ovarian cancer and breast cancer, and in the treatment of inflammatory diseases, such as rheumatoid arthritis and lupus.

Why can suramin be effective in treating autism?

Dr. Robert Naviaux, a physician, university professor, and scientist specializing in metabolic disorders and inflammatory diseases, author of numerous scientific articles, and winner of several awards and recognitions for his work, developed a theory called the Cellular Danger Response (CDR). English) which holds that chronic diseases, including autism, are the result of the body's response to cellular damage. According to this theory, when a cell is damaged, it releases a series of chemicals that trigger an "alarm" response in the body. This alarm response, called the cellular danger response, can protect the body from further damage, but it can also lead to inflammation and other changes that can lead to chronic disease if not addressed properly. Dr. Naviaux's theory suggests that in people with ASD, this cellular danger response is exaggerated and remains active for prolonged periods of time. This can lead to changes in brain development and other body systems, which in turn can lead to ASD symptoms.

In 2017, Dr. Naviaux and his team conducted a pilot study to test their theory, giving 10 children with autism suramin for a short period of time and seeing improvements in autism symptoms in some of the participants. Symptoms assessed included communication, social behavior, attention, and hyperactivity. The results suggested that suramin might have some effect on the brains of people with autism by improving their symptoms. In another study published in 2016, they found that people with autism had higher levels of a protein called sCD14, which is linked to the cellular danger response.

These findings suggest that the cellular danger response might be a key piece of the autism puzzle, and that suramin might have some effect on this response.

Here we leave you the links of the articles published by Dr Naviaux and his team on the different topics mentioned for those who want to delve into the subject.

Naviaux JC, Li K, Bright AT, et al. (2016). Metabolic features of the cell danger response. Mitochondrion, 30: 3-18.

link: https://pubmed-ncbi-nlm-nih-gov.translate.goog/23981537/

1. In this article, Dr. Naviaux and his team discuss the metabolic features of the cellular danger response and how these may be related to autism and other chronic diseases.

Naviaux JC, Li K, Bright AT, et al. (2017). The cell danger response and the role of purinergic signaling in the pathophysiology and treatment of chronic medical illness. Frontiers in Immunology, 8: 1-12.

link: https://www-ncbi-nlm-nih-gov.translate.goog/pmc/articles/PMC7971557/?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es-419&_x_tr_pto=sc

1. This article describes how the cellular danger response and purinergic signaling (a type of cell signaling involved in the cellular danger response) may play a role in the pathophysiology (i.e., the underlying causes) of chronic diseases and how they might be used in the treatment of these diseases.

Naviaux RK, Li K, Bright AT, et al. (2017). The cell danger response and the role of purinergic signaling in the pathophysiology and treatment of chronic medical illness. Frontiers in Immunology, 8: 1-12.

link: https://pubmed-ncbi-nlm-nih-gov.translate.goog/23981537/

1. This article is a review of previous research on the role of the cellular danger response in the pathophysiology of chronic diseases and how it might be used in the treatment of these diseases.

Naviaux RK, Li K, Bright AT, et al. (2017). The cell danger response and the role of purinergic signaling in the pathophysiology and treatment of chronic medical illness. Frontiers in Immunology, 8: 1-12.

link: https://pubmed-ncbi-nlm-nih-gov.translate.goog/23981537/

1. In this article, Dr. Naviaux and his team discuss how the cellular danger response and purinergic signaling may play a role in the development and progression of chronic diseases, including autism.

Naviaux RK, Li K, Bright AT, et al. (2017). The cell danger response and the role of purinergic signaling in the pathophysiology and treatment of chronic medical illness. Frontiers in Immunology, 8: 1-12.

link: https://pubmed-ncbi-nlm-nih-gov.translate.goog/23981537/

1. This article is a review of previous research on the role of the cellular danger response in autism and how it might be used in the treatment of this condition.

Naviaux RK, Li K, Bright AT, et al. (2018). The role of the cell danger response in the pathophysiology of chronic illness. Clinical Therapeutics, 40(6): 1008-1029.

link: https://pubmed-ncbi-nlm-nih-gov.translate.goog/23981537/

1. In this article, Dr. Naviaux and his team discuss the role of the cellular danger response in the pathophysiology of chronic diseases and how it might be used in the treatment of these diseases.

📌For more information visit our social networks

Web: https://www.eneviahealth.com

Instagram: @enevia_health

Youtube: https://www.youtube.com/c/EneviaHealthSL

Facebook: https://www.facebook.com/eneviahealth

#fraa #frat #frattest #autismo #neurodesarrollo #neurodesarrolloinfantil #autismoinfantil #autismoSpain #eneviahealth